Search Results - "Cohn, Allen Lee" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

by Tap, William D, Wainberg, Zev A, Anthony, Stephen P, Ibrahim, Prabha N, Zhang, Chao, Healey, John H, Chmielowski, Bartosz, Staddon, Arthur P, Cohn, Allen Lee, Shapiro, Geoffrey I, Keedy, Vicki L, Singh, Arun S, Puzanov, Igor, Kwak, Eunice L, Wagner, Andrew J, Von Hoff, Daniel D, Weiss, Glen J, Ramanathan, Ramesh K, Zhang, Jiazhong, Habets, Gaston, Zhang, Ying, Burton, Elizabeth A, Visor, Gary, Sanftner, Laura, Severson, Paul, Nguyen, Hoa, Kim, Marie J, Marimuthu, Adhirai, Tsang, Garson, Shellooe, Rafe, Gee, Carolyn, West, Brian L, Hirth, Peter, Nolop, Keith, van de Rijn, Matt, Hsu, Henry H, Peterfy, Charles, Lin, Paul S, Tong-Starksen, Sandra, Bollag, Gideon
Published in The New England journal of medicine (30.07.2015)

Get full text

Journal Article

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

by Tabernero, Josep, Dr, Yoshino, Takayuki, MD, Cohn, Allen Lee, MD, Obermannova, Radka, MD, Bodoky, Gyorgy, Prof, Garcia-Carbonero, Rocio, MD, Ciuleanu, Tudor-Eliade, Prof, Portnoy, David C, MD, Van Cutsem, Eric, Prof, Grothey, Axel, MD, Prausová, Jana, MD, Garcia-Alfonso, Pilar, PhD, Yamazaki, Kentaro, MD, Clingan, Philip R, Prof, Lonardi, Sara, MD, Kim, Tae Won, Prof, Simms, Lorinda, MS, Chang, Shao-Chun, PhD, Nasroulah, Federico, MD
Published in The lancet oncology (01.05.2015)

Get full text

Journal Article

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

by Lee, Chung-Han, Shah, Amishi Yogesh, Rasco, Drew, Rao, Arpit, Taylor, Matthew H, Di Simone, Christopher, Hsieh, James J, Pinto, Alvaro, Shaffer, David R, Girones Sarrio, Regina, Cohn, Allen Lee, Vogelzang, Nicholas J, Bilen, Mehmet Asim, Gunnestad Ribe, Sara, Goksel, Musaberk, Tennøe, Øyvind Krohn, Richards, Donald, Sweis, Randy F, Courtright, Jay, Heinrich, Daniel, Jain, Sharad, Wu, Jane, Schmidt, Emmett V, Perini, Rodolfo F, Kubiak, Peter, Okpara, Chinyere E, Smith, Alan D, Motzer, Robert J
Published in The lancet oncology (01.07.2021)

Get full text

Journal Article

Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer

Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer

by Sanoff, Hanna K., Goldberg, Richard M., Ivanova, Anastasia, O'Reilly, Seamus, Kasbari, Samer S., Kim, Richard D., McDermott, Ray, Moore, Dominic T., Zamboni, William, Grogan, William, Cohn, Allen Lee, Bekaii‐Saab, Tanios S., Leonard, Gregory, Ryan, Theresa, Olowokure, Olugbenga O., Fernando, Nishan H., McCaffrey, John, El‐Rayes, Bassel F., Horgan, Anne M., Sherrill, Gary Bradley, Yacoub, George Hosni, O'Neil, Bert H.
Published in Cancer (01.08.2018)

Get full text

Journal Article

Open-label phase II/III study of nivolumab plus standard of care versus standard of care for first-line treatment of metastatic colorectal cancer: Checkmate-9X8

Open-label phase II/III study of nivolumab plus standard of care versus standard of care for first-line treatment of metastatic colorectal cancer: Checkmate-9X8

by Tabernero, Josep, Yoshino, Takayuki, Cohn, Allen Lee, Kochenderfer, Mark D., Holdridge, Regan C., Couture, Felix, Elez, Elena, Bendell, Johanna C., Zhou, Ming, Cullen, Dana, Lenz, Heinz-Josef
Published in Journal of clinical oncology (01.02.2019)

Get full text

Journal Article

Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study

Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study

by Yoshino, Takayuki, Obermannova, Radka, Bodoky, Gyorgy, Prausová, Jana, Garcia-Carbonero, Rocio, Ciuleanu, Tudor-Eliade, Garcia Alfonso, Pilar, Portnoy, David Craig, Cohn, Allen Lee, Van Cutsem, Eric, Yamazaki, Kentaro, Clingan, Philip, Muro, Kei, Kim, Tae Won, Wijayawardana, Sameera R., Hozak, Rebecca, Nasroulah, Federico, Tabernero, Josep
Published in Journal of clinical oncology (01.02.2018)

Get full text

Journal Article

Exploratory analysis of left- versus right-sided colorectal carcinoma in RAISE: A randomized, double-blind, phase 3 trial of ramucirumab (RAM) + FOLFIRI versus placebo (PBO) + FOLFIRI

Exploratory analysis of left- versus right-sided colorectal carcinoma in RAISE: A randomized, double-blind, phase 3 trial of ramucirumab (RAM) + FOLFIRI versus placebo (PBO) + FOLFIRI

by Portnoy, David Craig, Obermannova, Radka, Bodoky, Gyorgy, Prausová, Jana, Garcia-Carbonero, Rocio, Ciuleanu, Tudor-Eliade, Garcia Alfonso, Pilar, Cohn, Allen Lee, Van Cutsem, Eric, Yamazaki, Kentaro, Yoshino, Takayuki, Lonardi, Sara, Kim, Tae Won, Yamaguchi, Kensei, Grothey, Axel, O Connor, Juan Manuel, Hsu, Yanzhi, Ferry, David, Nasroulah, Federico, Tabernero, Josep
Published in Journal of clinical oncology (01.02.2017)

Get full text

Journal Article

Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)

Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)

by Verslype, Chris, Cohn, Allen Lee, Kelley, Robin Katie, Yang, Tsai-Shen, Su, Wu-Chou, Ramies, David A., Lee, Yihua, Shen, Xiaodong, Van Cutsem, Eric
Published in Journal of clinical oncology (20.05.2012)

Get full text

Journal Article

Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT)

Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT)

by Cohn, Allen Lee, Kelley, Robin Katie, Yang, Tsai-Shen, Su, Wu-Chou, Verslype, Chris, Ramies, David A., Lee, Yihua, Shen, Xiaodong, Van Cutsem, Eric
Published in Journal of clinical oncology (01.02.2012)

Get full text

Journal Article

Phase 2 study of nab- sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas

Phase 2 study of nab- sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas

by Demeure, Michael J., Cohn, Allen Lee, Seery, Tara Elisabeth, Ding, Li, Navarro, Willis H., Paulson, Andrew Scott
Published in Journal of clinical oncology (20.01.2024)

Get full text

Journal Article

Safety, tolerability and efficacy of 212 Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study

Safety, tolerability and efficacy of 212 Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study

by Strosberg, Jonathan R., Naqvi, Shagufta, Cohn, Allen Lee, Delpassand, Ebrahim S, Wagner, Volker Jean, Tworowska, Izabela, Torgue, Julien, Woloski, Rachel, Manuel, Allison, Maluccio, Mary Alice
Published in Journal of clinical oncology (01.06.2024)

Get full text

Journal Article

Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial

Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial

by Javle, Milind M., Mahipal, Amit, Kankeu Fonkoua, Lionel Aurelien, Fountzilas, Christos, Li, Daneng, Pelster, Meredith, Liao, Chih-Yi, Richards, Donald A., Deming, Dustin A., Younes, Mohamad Ahmad, Mantry, Parvez, Cohn, Allen Lee, Kingsley, Ed, Fan, Jean, Peng, Peng, Sun, Caixia, Wang, Hui, Hennessy, Katie, Shan, Yujun, Wu, Frank
Published in Journal of clinical oncology (20.01.2024)

Get full text

Journal Article

Surufatinib in U.S. patients with soft tissue sarcoma

Surufatinib in U.S. patients with soft tissue sarcoma

by Movva, Sujana, Spira, Alexander I., Hamilton, Erika P., Wang, Judy S., Cohn, Allen Lee, Strauss, James F., Stacchiotti, Silvia, Tucci, Chris, Kauh, John, Nanda, Shivani, Kania, Marek K., Patel, Shreyaskumar
Published in Journal of clinical oncology (01.06.2022)

Get full text

Journal Article

A randomized, phase II study of high-risk colorectal cancer patients (stage IIIC) treated with either regorafenib or standard of care (no treatment) after adjuvant FOLFOX

A randomized, phase II study of high-risk colorectal cancer patients (stage IIIC) treated with either regorafenib or standard of care (no treatment) after adjuvant FOLFOX

by Cartwright, Thomas H., Cohn, Allen Lee, Richards, Donald A.
Published in Journal of clinical oncology (01.02.2016)

Get full text

Journal Article

Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146

Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146

by Lee, Chung-Han, Yogesh Shah, Amishi, Rao, Arpit, Taylor, Matthew H., Di Simone, Christopher, Hsieh, James J., Pinto, Alvaro, Gironés Sarrió, Regina, Lee Cohn, Allen, Asim Bilen, Mehmet, Gunnestad Ribe, Sara, Krohn Tennøe, Øyvind, Richards, Donald, Sweis, Randy F., Courtright, Jay, Heinrich, Daniel, Perini, Rodolfo, Kubiak, Peter, Bock, Daena, Okpara, Chinyere E., Motzer, Robert J.
Published in European urology (21.05.2024)

Get full text

Journal Article

Final database lock results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma

Final database lock results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma

by Lee, Chung-Han, Yogesh Shah, Amishi, Rao, Arpit, Taylor, Matthew H, Pinto, Alvaro, Girones Sarrio, Regina, Lee Cohn, Allen, Asim Bilen, Mehmet, Gunnestad Ribe, Sara, Goksel, Musaberk, Tennøe, Øyvind Krohn, Richards, Donald, Sweis, Randy F, Heinrich, Daniel, Perini, Rodolfo, Kubiak, Peter, Huang, Jie, Motzer, Robert J
Published in The oncologist (Dayton, Ohio) (23.08.2023)

Get full text

Journal Article

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

by Tap, William D, Singh, Arun S, Anthony, Stephen Patrick, Sterba, Mike, Zhang, Chao, Healey, John H, Chmielowski, Bartosz, Cohn, Allen Lee, Shapiro, Geoffrey I, Keedy, Vicki L, Wainberg, Zev A, Puzanov, Igor, Cote, Gregory M, Wagner, Andrew J, Braiteh, Fadi, Sherman, Eric, Hsu, Henry H, Peterfy, Charles, Gelhorn, Heather L, Ye, Xin, Severson, Paul, West, Brian L, Lin, Paul S, Tong-Starksen, Sandra
Published in Clinical cancer research (15.01.2022)

Get full text

Journal Article

Initial safety results from a randomized, phase II study of high-risk colorectal cancer patients (stage IIIC) treated with either regorafenib or standard of care (no treatment) after adjuvant FOLFOX

Initial safety results from a randomized, phase II study of high-risk colorectal cancer patients (stage IIIC) treated with either regorafenib or standard of care (no treatment) after adjuvant FOLFOX

by Cartwright, Thomas H., Nguyen, Thu-Cuc, Cohn, Allen Lee, Richards, Donald A.
Published in Journal of clinical oncology (20.05.2017)

Get full text

Journal Article

Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC)

Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC)

by Fakih, Marwan, Raghav, Kanwal Pratap Singh, Chang, David Z., Larson, Timothy, Cohn, Allen Lee, Huyck, Timothy K., Cosgrove, David, Fiorillo, Joseph A., D'Adamo, David R., Hammell, Amy, Sharma, Neelesh, Coppieters, Sabine, Schulz, Anke, Seidel, Henrik, Herpers, Matthias, Soares Viana de Oliveira, Carolina, Paulson, Andrew Scott, Wang, Ying A.
Published in Journal of clinical oncology (01.02.2022)

Get full text

Journal Article

Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8

Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8

by Lenz, Heinz-Josef, Parikh, Aparna Raj, Spigel, David R., Cohn, Allen Lee, Yoshino, Takayuki, Kochenderfer, Mark D., Elez, Elena, Shao, Spencer H., Deming, Dustin A., Holdridge, Regan C., Larson, Timothy, Chen, Eric, Mahipal, Amit, Ucar, Antonio, Cullen, Dana, Baskin-Bey, Edwina S, Ledeine, Jean-Marie, Hammell, Amy, Tabernero, Josep
Published in Journal of clinical oncology (01.02.2022)

Get full text

Journal Article